Reaction: New fusion protein tested for glioblastoma treatment
A team of scientists led by the University Hospital Zurich (Switzerland) has tested a new treatment for glioblastoma, a highly aggressive nervous system tumour with a poor prognosis. The therapy consists of a fusion protein that combines the TNF factor - a key factor in the processes of inflammation and immune response - with an antibody that targets the tumour matrix. The researchers, whose results are published in the journal Science Translational Medicine, have studied its action together with a type of chemotherapy both in mice and in six patients included in a phase 1 clinical trial.